West Nile Fever Clinical Trial
Official title:
Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults.
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
Currently, the only method of prevention of West Nile infection is control of the mosquito vectors associated or avoidance of mosquito bites, which has proven largely ineffective. Developing a safe, effective vaccine and making it widely available will enhance the prospects of prevention and control of this disease. In addition, natural infections with the YF virus and WN virus are more severe in the elderly. Therefore, a study among healthy older subjects or those with well controlled chronic diseases will provide data to determine a ChimeriVax-WN02 vaccine dose that is immunogenic and well tolerated. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04371003 -
Prospective Investigation of Oxidative Stress in West Nile Virus Infection
|
||
| Terminated |
NCT00091845 -
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
|
Phase 1 | |
| Terminated |
NCT00927953 -
Treatment of West Nile Virus With MGAWN1
|
Phase 2 | |
| Completed |
NCT00300417 -
Phase I Study of West Nile Virus Vaccine
|
Phase 1 | |
| Completed |
NCT00106769 -
Vaccine to Prevent West Nile Virus Disease
|
Phase 1 | |
| Completed |
NCT00537147 -
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00442169 -
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
|
Phase 2 |